Paeoniflorin preparations and uses thereof for fat reduction

Abstract

Disclosed are methods and preparations useful for reducing fat at a targeted area(s) on a human. The preparations comprise as an active ingredient an adipolysis enhancing (i.e., fat-melting) amount of an active ingredient, paeoniflorin (PF). The preparations may be provided as an injectable preparation or as a topically applied preparation, such as in the form of a crème or lotion. In topical preparations, the active ingredient paeoniflorin may be contained within nanospheres, such as albumin nanospheres. The PF-containing preparations may also include a permeant, such as azone. The method may be accompanied by the application of ultrasound to the area being treated prior to, during or after, or prior to, during, and after application of the paeoniflorin preparation to an area of the body in which fat reduction is desired. By way of example, the methods and preparations are effective for reducing targeted fat deposits at various anatomical sites of the body, such as the midsection (“love handles”), jowls, hips, arms, thighs and buttocks area.

What is claimed is: 
     
         1 . A method for enhancing fat loss in a human comprising:
 administering an adipolysis enhancing paeoniflorin preparation comprising paeoniflorinin and a liquid carrier to a human;   enhancing fat loss in the human, wherein fat loss in the human provided the paeoniflorin preparation is enhanced compared to fat loss in a human not provided the paeoniflorin preparation.   
     
     
         2 . The method of  claim 1  wherein the paeoniflorin preparation is not an injectable preparation. 
     
     
         3 . The method of  claim 1  wherein the paeoniflorin preparation comprises a concentration of paeoniflorin of about 0.02 mg/0.5 ml to about 0.25 mg/0.5 ml. 
     
     
         4 . The method of  claim 1  wherein the paeoniflorin preparation comprises a concentration of paeoniflorin of about 0.25 mg/0.5 ml. 
     
     
         5 . The method of  claim 1  wherein the paeoniflorin preparation comprises a concentration of paeoniflorin of about 0.2 mg/ml to about 0.3 mg/ml. 
     
     
         6 . The method of  claim 1  wherein the paeoniflorin preparation comprises a concentration of paeoniflorin of about 0.5 mg/ml. 
     
     
         7 . An adipolysis enhancing and subcutaneous fat reducing preparation comprising an adipolysis enhancing amount of paeoniflorin in a suitable carrier, wherein the adipolysis enhancing amount of paeoniflorin in the preparation is a concentration of paeoniflorin of about 0.02 mg/0.5 ml to about 0.25 mg/0.5 ml. 
     
     
         8 . The adipolysis enhancing and subcutaneous fat reducing preparation of  claim 7  wherein the carrier is water. 
     
     
         9 . The adipolysis enhancing and subcutaneous fat reducing preparation of  claim 7  further comprising a permeant. 
     
     
         10 . The adipolysis enhancing and subcutaneous fat reducing preparation of  claim 7  comprising a concentration of paeoniflorin of about 0.25 mg/0.5 ml. 
     
     
         11 . The adipolysis enhancing and subcutaneous fat reducing preparation of  claim 7 , said preparation containing a concentration of paeoniflorin that increases cyclic AMP levels in adipocytes compared to cyclic AMP levels in adipocytes in the absence of the concentration of paeoniflorin. 
     
     
         12 . The adipolysis enhancing and subcutaneous fat reducing preparation of  claim 7  comprising a concentration of paeoniflorin of about 0.2 mg/ml to about 0.3 mg/ml. 
     
     
         13 . The adipolysis enhancing and subcutaneous fat reducing preparation of  claim 7  comprising a liquid preparation. 
     
     
         14 . The adipolysis enhancing and subcutaneous fat reducing preparation of  claim 7  comprising a concentration of paeoniflorin of about 1 umol/L to about 5 umol/L. 
     
     
         15 . An adipolysis enhancing and subcutaneous fat reducing preparation comprising an adipolysis enhancing amount of paeoniflorin in a suitable carrier, wherein the adipolysis enhancing amount of paeoniflorin in the preparation is about 11 moles/Liter. 
     
     
         16 . The adipolysis enhancing and subcutaneous fat reducing preparation of  claim 15  comprising a liquid preparation. 
     
     
         17 . The adipolysis enhancing and subcutaneous fat reducing preparation of  claim 16  wherein the suitable carrier is water.